Phillips Medisize

A close-up image of a Metered Dose Inhaler against a navy blue background

Pressurized Metered-dose Inhaler (pMDI)

For many patients, pressurized metered-dose inhalers remain an important device option.

All the components of a pMDI have important roles in determining the characteristics of the aerosol and drug delivery to the lungs. With extensive expertise in pMDI development and life cycle management, we can help develop a new pMDI product or optimize your formulation and device performance.

Our particular areas of expertise include:

  • Developing tailored solutions based on commercially available pMDI devices
  • Optimizing container closure systems to be compatible with pMDI formulations
  • Designing for high-volume and low-cost manufacture

We have a track record of supporting successful pMDI developments, including flutiform™ and breath-actuated flutiform™ K-haler™.

flutiform™ is a registered trademark of Jagotec AG, a Vectura company AG. K-haler™ is a registered trademark of Mundipharma AG.

Phillips Medisize employee working in the pharmaceutical technology service lab, while we can see another employee walk past outside the window. Through the window, another corridor shows another employee in a neighbouring room.

INHALATION THERAPIES EXPERTISE

Backed by world-class capabilities, we provide proven inhalation services: product development, formulation, pharmaceutical analysis, custom device design, and clinical-trial production and supply.

Learn More

Featured Resources

Publication
FOX™ Vibrating Mesh Nebulizer from Phillips Medisize
ODD: Integrating Phillips Medisize and Vectura’s Operations
In this interview, Phillips Medisize’s Charlie Schumacher and Sandy Munro discuss the company’s progress on its integration of Vectura. Learn more.
Publication
OnDrug Delivery July 2025 cover.
ODD: Phillips Medisize Grows its Capabilities with Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson of Phillips Medisize discuss the company’s expanded capabilities as a result of its recent acquisition of Vectura. Learn more.
Publication
OIC
PMPS: Elevate Your Molecule
Phillips Medisize’s 2025 acquisition of Vectura expanded its offerings to include inhaled drug development for small molecules, biologics and complex combinations for both novel and generic products. Learn more.

Are You Ready to Advance Lifesaving Innovations?

Bring Your Drug Delivery Device to Life